Swedish Orphan Biovitrum (Sobi) is an integrated biotechnology company that researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The Company offers Elocta to treat haemophilia A, and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1, and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. Swedish Orphan Biovitrum manufactures drug substance for ReFacto AF, and develops BIVV001 and BIVV002 for the treatment of hemophilia.